In a retrospective analysis of 58 patients receiving anti-PD-1 ICI for advanced NSCLC, a subset of patients with ALK-rearrangement had low PD-L1 expression, low CD8+ TILs, and low response rates to anti-PD1 blockade [52]. Here, CD8A is linked to non-small cell lung carcinoma.